Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 12/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | TOP2A | P11388 | 2/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12073506 | 0.89 | NISCH (0.81) | NISCHLMNARECQLHTR1DADRA1A | |
| SCHEMBL1935142 | 0.86 | NISCH (0.75) | NISCHLMNARECQLHTR1DADRA1A | |
| Hydrochloric Acid SCHEMBL1936498 | 0.84 | NISCH (0.73) | NISCHLMNARECQLHTR1DADRA1A | |
| SCHEMBL5476725 | 0.84 | NISCH (0.79) | NISCHLMNARECQLHTR1DADRA1A | |
| SCHEMBL17084449 | 0.80 | NISCH (0.66) | NISCHMAOB | |
| SCHEMBL1886692 | 0.79 | NISCH (1.00) | NISCHLMNARECQLHTR1DADRA1A | |
| SCHEMBL1685409 | 0.79 | NISCH (0.66) | NISCHLMNARECQLHTR1DADRA1A | |
| SCHEMBL523059 | 0.79 | LMNA (0.96) | NISCHLMNARECQLHTR1DADRA1A | |
| SCHEMBL23758890 | 0.78 | TDP1 (0.82) | NISCHLMNA | |
| SCHEMBL8188355 | 0.77 | LMNA (0.92) | NISCHLMNARECQLHTR1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782390-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9782390-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170100379-A1 | AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AAAS, MGAM, PAM | NISCH 36/4885LMNA 657/4885RECQL 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.